The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Abstract
The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins compete with the natural substrate for the enzyme's active site, preventing the formation of a functional enzyme structure with reversible binding [11] .”
From Statins as antifungal agents (2011) · cites this paper as [11]
In the citing paper
“Statins are not applicable as single antifungal agents for the treatment of IFI because their MICs are much higher (about 1 order of magnitude) than their maximum achievable concentrations in human serum [11,[40][41][42][43][44][45] .”
From Statins as antifungal agents (2011) · cites this paper as [11]
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 9,216
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018
Research works printed but not linked: 8
- Fischer, 1999, The HMG-CoA reductase inhibitor fluvastatin, Drug Metab Dispos, 27, 410
- Henwood, 1995, Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia, Drugs, 31, 9
- Hoffman, 1992, The interaction of lovastatin and warfarin, Conn Med, 56, 107
- Mai, 1997, Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporin A (CSA), Eur J Clin Pharmacol, 52, A137
- Raiteri, 1997, Pharmacological control of the mevalonate pathway, J Pharmacol Exp Ther, 281, 1144
- 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
- Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat, J Pharmacol Exp Ther, 257, 1225
- Soma, 1995, In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug, Cancer Res, 55, 597
Cited by
Sorted by citations
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research; Group, T. A. O. A. C. F. T. A. C. R. G. (2002) · JAMA · doi:10.1001/jama.288.23.2998 · Cited by 1,328
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,247
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911
Clinical Pharmacokinetics of Atorvastatin
s, H. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 636
Metadata
- Authors
- Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F.
- Affiliations
- University of Milan (IT)
- University of Parma (IT)
- Corresponding author
- Corsini, Alberto
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 84
- Issue
- 3
- Pages
- 413-428
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2045063002
- Cited by
- 796
- References
- 186
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 27 · 2023: 19 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 14 · 2018: 21 · 2017: 30 · 2016: 30 · 2015: 27 · 2014: 35 · 2013: 31 · 2012: 38
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, pharmacokinetics, pharmacodynamics, HMG-CoA reductase inhibition, mevalonate, pleiotropy, smooth muscle cell proliferation, macrophage cholesterol accumulation, atherosclerosis, drug interactions, CYP3A4, cyclosporine, rhabdomyolysis, myositis, pravastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, cerivastatin
- MeSH terms
- Atorvastatin, Fluvastatin, Animals, Anticholesteremic Agents, Cell Division, Cytochrome P-450 Enzyme System, Drug Interactions, Fatty Acids, Monounsaturated, Heptanoic Acids, Humans, Indoles, Mevalonic Acid, Pyridines, Pyrroles, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
